GET DAILY SIGNALSPharvaris (PHVS): Analyst Consensus at $60 Points to +76% Upside From Current Levels
Key Takeaways
- The central stock price target of $60 is the arithmetic mean of roughly 14 current Wall Street analyst price targets, rounded to a clean level from an underlying average near $61.
- With PHVS trading around $34, reaching $60 would require a gain of roughly 76%, a very large move from current levels.
- Individual analyst price targets span a wide range from about $44 to $79, reflecting genuine disagreement over how to value a pre-revenue biotechnology company.
- The strongest supporting factor is positive Phase 3 data for deucrictibant, an oral hereditary angioedema (HAE) therapy, which triggered a wave of target increases in September 2026.
- The biggest risks are regulatory uncertainty, ongoing cash burn with no product revenue, competition in HAE, and the possibility of valuation compression or share dilution.
- You can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for deeper context.
- For additional market insight, explore Trending AI Robots to see AI-driven strategies monitoring stocks and ETFs like PHVS.
Analyst Price Targets and Consensus View
Pharvaris N.V. (PHVS) is a late-stage, clinical-stage biopharmaceutical company based in Leiden, the Netherlands, developing oral bradykinin B2-receptor antagonists for hereditary angioedema and related rare diseases. Because it is pre-revenue, its valuation rests almost entirely on the clinical and regulatory outlook for its lead asset, deucrictibant.
The $60 central target reflects roughly 14 verified, current analyst price targets. The underlying arithmetic mean is approximately $61, rounded to $60 for readability. The range is unusually wide, from about $44 at the low end (Guggenheim and Bank of America) to $79 at the high end (Citizens JMP), with most targets clustered in the $50 to $65 zone. Recent actions include Wells Fargo at $65, Morgan Stanley at $62, RBC Capital at $62, Cantor Fitzgerald and Leerink Partners at $65, H.C. Wainwright at $60, and Wedbush at $50. Bank of America upgraded the shares to Buy with a $44 target in late October 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The wide spread reflects genuine analytical disagreement: bullish analysts emphasize deucrictibant's oral convenience and positive Phase 3 results, while cautious analysts weigh execution, regulatory, and competitive risk. This figure is a calculated average, not an official published consensus, and it is not a guarantee of future performance.
Current Market Position and Path Toward the Target
Shares of PHVS trade near $34, within a 52-week range of roughly $21 to $43. Reaching the $60 average analyst price target would require upside of approximately 76%, which qualifies as a very large move. The stock rallied strongly in mid-2026 on positive Phase 3 data but has since pulled back from its highs near $43.
The path toward $60 would likely depend on continued positive clinical readouts, a successful regulatory filing, and eventual U.S. Food and Drug Administration (FDA) approval of deucrictibant. As a clinical-stage company with no product revenue and a reported net loss, Pharvaris' valuation is driven by milestones rather than current earnings, so the move would need to be justified by de-risking of the pipeline rather than near-term fundamentals.
What Could Support a Move Toward the Target
The central catalyst is deucrictibant, being developed as both an immediate-release capsule (PHVS416) for on-demand HAE attack treatment and an extended-release tablet (PHVS719) for prophylaxis. Positive Phase 3 RAPIDe-3 results for the immediate-release formulation, along with Phase 3 data showing the extended-release formulation substantially reduced HAE attack rates, drove the September 2026 wave of analyst target increases.
An oral therapy offers meaningful convenience relative to injectable HAE treatments, a differentiator analysts have highlighted. A strong cash position supports development through key milestones, and broadly bullish ratings (nearly all covering analysts rate the stock Buy or equivalent) reflect a favorable professional view of the risk-reward. A potential regulatory submission and eventual approval decision represent additional de-risking events that could support a higher valuation.
What Could Prevent the Target From Being Reached
Pharvaris remains pre-revenue with ongoing losses and cash burn, so execution risk is material. Regulatory review can delay or derail approval, and clinical data, however promising, is not a guarantee of commercial success. The HAE market is competitive, including oral options such as BioCryst's (BCRX) Orladeyo and injectable therapies from larger players, which could pressure pricing and market share.
Additionally, the shares trade on expectations rather than earnings, leaving them vulnerable to valuation compression if sentiment shifts. Further share issuance to fund operations could dilute existing holders, and the wide analyst target range signals that some professionals see substantially less upside than the average implies.
Technical Levels and Market Structure
The 52-week high near $43 represents a meaningful resistance zone, as the stock has already reversed from that area once. The $40 round-number level and the prior peak near $43 are the clearest overhead markers on the way toward $60. On the downside, the low-$30s area near the current price and the 52-week low near $21 mark key support levels. The stock's pullback of roughly 20% from its 52-week high shows how quickly sentiment-driven biotech moves can reverse.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact period varies by firm and is rarely stated explicitly. Investors should watch upcoming clinical data readouts, the timing and acceptance of any regulatory submission for deucrictibant, and guidance on cash runway and financing plans. Analyst rating and target revisions, insider transactions, and competitive developments in the HAE space will also be important. Regulatory decisions, once a filing is made, represent the single most consequential near-term catalyst.
Using Tickeron AI Daily Buy/Sell Signals in Practice
For traders seeking a more dynamic view, Tickeron's AI Daily Buy/Sell Signals offer a technology-driven complement to traditional analyst research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I have found these signals helpful for spotting momentum shifts in names like PHVS without replacing the fundamental analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening allows. Investors following PHVS may find this an efficient way to track evolving momentum alongside the fundamental picture.
Final Assessment
The question of whether Pharvaris can reach $60 ultimately rests on execution across clinical, regulatory, and eventually commercial milestones rather than any near-term earnings trajectory. The $60 figure is a calculated average of roughly 14 analyst targets spanning $44 to $79, requiring a very large gain of about 76% from the current price near $34. Support comes from encouraging Phase 3 data and an oral-dosing advantage, while the principal obstacles are regulatory risk, a pre-revenue profile with ongoing cash burn, and a competitive HAE market. With analysts disagreeing widely on fair value, investors should focus on the next data readouts, the regulatory filing path, and revisions to analyst expectations rather than treating the average target as a forecast or a certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PHVS in upward trend: price rose above 50-day moving average on November 06, 2026
PHVS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PHVS as a result. In 98 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PHVS just turned positive on October 20, 2026. Looking at past instances where PHVS's MACD turned positive, the stock continued to rise in 49 of 55 cases over the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for PHVS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHVS advanced for three days, in 192 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
PHVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for PHVS moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where PHVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for PHVS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.026) is normal, around the industry mean (3.498). P/E Ratio (-13.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PHVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement